Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | MGLL | Q99685 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MGAM | O43451 | 2/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.44 |
| ▸ | SI | P14410 | 2/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13963730 | 0.86 | FAAH (0.45) | EGLN3FAAHMGLLGAARAB9A | |
| SCHEMBL12672863 | 0.76 | SLC9A1 (0.55) | FAAHMGLLGAAALDH1A1LMNA | |
| SCHEMBL14200027 | 0.76 | FAAH (0.38) | FAAHMGLLGAAALDH1A1 | |
| SCHEMBL13178731 | 0.76 | FAAH (0.38) | FAAHMGLLGAAALDH1A1LMNA | |
| SCHEMBL28681996 | 0.75 | FAAH (0.58) | FAAHMGLLGAAMGAMAMY1A | |
| SCHEMBL361654 | 0.75 | GAA (0.73) | EGLN3GAARAB9AMGAMAMY1A | |
| SCHEMBL29625506 | 0.75 | GAA (0.73) | EGLN3GAARAB9AMGAMAMY1A | |
| SCHEMBL17083748 | 0.74 | FAAH (0.36) | FAAHMGLLGAAALDH1A1 | |
| SCHEMBL13139601 | 0.74 | FAAH (0.36) | FAAHMGLLGAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL1371916 | 0.73 | GAA (0.71) | EGLN3GAARAB9AMGAMAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190248791-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS SA (CH) | 2019-08-15 | — | — | US | disclosed |
| US-10174034-B2 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | RHIZEN PHARMACEUTICALS SA (CH) | 2019-01-08 | — | — | US | disclosed |
| EP-2509974-B1 | PYRAZOLES DERIVATIVES MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS S A (CH) | 2018-04-11 | — | — | EP | disclosed |
| US-20150291588-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS SA (CH) | 2015-10-15 | — | — | US | disclosed |
| US-8993612-B2 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | RHIZEN PHARMACEUTICALS SA (CH) | 2015-03-31 | — | — | US | disclosed |
| EP-2509974-A1 | PYRAZOLES DERIVATIVES MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON- SMALL CELL LUNG CANCER | Rhizen Pharmaceuticals S.A. (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20110112058-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | US | disclosed |
| WO-2011042798-A1 | PYRAZOLES DERIVATIVES MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON- SMALL CELL LUNG CANCER | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112058-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | EGLN3 3961/4885FAAH 2227/4885MGLL 2324/4885 |
| US-20190248791-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | EGLN3 3961/4885FAAH 2227/4885MGLL 2324/4885 |
| US-20150291588-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | EGLN3 3961/4885FAAH 2227/4885MGLL 2324/4885 |
| US-10174034-B2 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | ORAI1, CACNA1E, CACNB2 | EGLN3 3840/4885FAAH 2213/4885MGLL 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.